Your browser doesn't support javascript.
loading
Optimal sampling times in bioequivalence tests.
Kong, F H; Gonin, R.
Affiliation
  • Kong FH; Westat, Rockville, Maryland 20850, USA.
J Biopharm Stat ; 10(1): 31-44, 2000 Feb.
Article in En | MEDLINE | ID: mdl-10709799
ABSTRACT
In bioequivalence studies, drug formulations are compared in terms of bioavailability parameters such as the area under the concentration-time curve (AUC), the maximum concentration (Cmax), and the time to maximum concentration (t(max)). Accuracy in measuring these parameters directly affects the accuracy of bioequivalence tests. Because the number of blood draws per patient is limited, the blood collection times must be spaced so that concentration-time curve measurements can produce accurate bioavailability parameter estimates. This paper describes an optimization approach for calculating optimal time designs for one-compartment models, but is sufficiently general for other compartmental models. Simulation indicates that the optimal design improves the accuracy of AUC estimation.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Therapeutic Equivalency / Models, Biological Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: J Biopharm Stat Year: 2000 Document type: Article
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Therapeutic Equivalency / Models, Biological Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: J Biopharm Stat Year: 2000 Document type: Article